Publicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (15)

2024

  1. GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR

    Radiotherapy and Oncology, Vol. 201

  2. Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    Neuro-oncology, Vol. 25, Núm. 1, pp. 37-53

  3. Interventional Radiotherapy (Brachytherapy) for the Treatment of Primary Lesions in Nasal Vestibule Malignancies

    Malignancies of the Nasal Vestibule: A New Perspective on Classification, Staging, and Treatment (Springer International Publishing), pp. 135-144

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

2020

  1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

2019

  1. Clinical presentation, diagnosis and staging of cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 98-107

2016

  1. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

    Drugs, Vol. 76, Núm. 9, pp. 925-945

2015

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014

    Journal of Translational Medicine, Vol. 13, Núm. 1

  2. PD-L1 expression as a potential predictive biomarker

    The Lancet Oncology

2014

  1. Awareness and understanding of cancer immunotherapy in Europe

    Human Vaccines and Immunotherapeutics, Vol. 10, Núm. 7, pp. 1828-1835

  2. Therapeutic vaccines for cancer: An overview of clinical trials

    Nature Reviews Clinical Oncology, Vol. 11, Núm. 9, pp. 509-524